A new impetus for the identification of LS in patients with CRC has arisen from the emergence of immunotherapy based on PD-L1 (programmed cell death ligand 1) blockade, with pembrolizumab being the first site-agnostic agent to be licensed for cancer treatment. The gene discussed is CD274; the disease is cancer.